Non-small Cell Lung Cancer Treatment by Stage Learn about treatment options for non-small cell lung cancer (NSCLC), including surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy
Neoadjuvant vs Adjuvant Chemoimmunotherapy for Stage II-IIIB Non-Small . . . In patients with resectable non-small cell lung cancer (NSCLC), recent trials demonstrate survival benefit of chemoimmunotherapy over chemotherapy alone in both the neoadjuvant and adjuvant settings To date, there is no direct comparison between neoadjuvant and adjuvant protocols We compared neoadjuvant vs adjuvant chemoimmunotherapy for resectable stage II-IIIB NSCLC
Comparing Impact of Treatment Before or After Surgery in Patients with . . . Description This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before surgery (neoadjuvant) and after surgery in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable) The usual approach for patients with resectable NSCLC is chemotherapy and or immunotherapy before surgery, after
Neoadjuvant immunotherapy strategies for resectable non-small cell lung . . . About one third of patients with Non-Small Cell Lung Cancer (NSCLC) presents at diagnosis with localized or locally advanced disease amenable to curative surgical resection Surgical operability refers to stage I to IIIA and selected stage IIIB NSCLC One of the main challenges in the management of early-stage resectable NSCLC is the optimization of available therapeutic strategies to prevent
Neoadjuvant Immunochemotherapy for Stage II-IIIB Non-Small Cell Lung . . . Neoadjuvant immunochemotherapy (neoICT) is not currently recommended for patients with stage II-IIIB non-small cell lung cancer (NSCLC) harboring oncogenic driver mutations, especially tyrosine kinase inhibitor–sensitizing epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) This study aimed to compare the pathologic response and survival outcomes between neoICT and
Immunotherapy for Resectable Non–Small Cell Lung Cancer—Not If, But . . . Over the past 5 years, immunotherapy has transformed the management of resectable early-stage non–small cell lung cancer (NSCLC) Historically, only platinum-based chemotherapy was given perioperatively to reduce the risk of recurrence after definitive surgical resection However, recurrence rates
Perioperative Immunotherapy for Node-Negative Non-Small Cell Lung . . . Neoadjuvant immunotherapy has gone from an idea to an indication in locally advanced lung cancer Several phase III trials have demonstrated the superiority of neoadjuvant chemoimmunotherapy compared with chemotherapy in this setting Although such progress has revolutionized the treatment of locally advanced disease, the unmet needs of stage I and stage II patients without lymph node disease
Immunotherapy for Non-Small Cell Lung Cancer They can be given with or without chemotherapy, with or without a CTLA-4 inhibitor (see below), before or after surgery for early-stage lung cancer, or for a long period of time for advanced-stage lung cancers
Cemiplimab and Fianlimab before Surgery for the Treatment of Stage IB . . . Description This phase II trial tests how well a fixed dose combination (FDC) of cemiplimab and fianlimab before surgery (neoadjuvant) works in treating patients with stage IB-IIIB non-small cell lung cancer (NSCLC) The current standard of care (SOC) for NSCLC is to give chemotherapy and immunotherapy before going to surgery to have the cancer removed (neoadjuvant therapy) Immunotherapy with